KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Operating Expenses (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Operating Expenses for 18 consecutive years, with $3.0 billion as the latest value for Q1 2026.

  • For Q1 2026, Operating Expenses rose 21.56% year-over-year to $3.0 billion; the TTM value through Mar 2026 reached $11.3 billion, up 10.1%, while the annual FY2025 figure was $10.8 billion, 5.42% up from the prior year.
  • Operating Expenses hit $3.0 billion in Q1 2026 for Regeneron Pharmaceuticals, down from $3.0 billion in the prior quarter.
  • Across five years, Operating Expenses topped out at $3.0 billion in Q4 2025 and bottomed at $1.7 billion in Q1 2022.
  • Average Operating Expenses over 5 years is $2.4 billion, with a median of $2.4 billion recorded in 2025.
  • Year-over-year, Operating Expenses fell 2.46% in 2022 and then soared 31.49% in 2023.
  • Regeneron Pharmaceuticals' Operating Expenses stood at $2.3 billion in 2022, then rose by 8.55% to $2.5 billion in 2023, then rose by 13.72% to $2.8 billion in 2024, then grew by 7.34% to $3.0 billion in 2025, then dropped by 1.39% to $3.0 billion in 2026.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $3.0 billion, $3.0 billion, and $2.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.